SCHEMBL1521660

SCHEMBL1521660

CCOC(=O)C(C)(C)c1cc(N)n(C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
CNR2 P34972 6/20 0.39
TSHR P16473 3/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
MAPK14 Q16539 1/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 2/20 0.36
GRN P28799 1/20 0.36
SORT1 Q99523 1/20 0.36
HPGD P15428 2/20 0.36
GAA P10253 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
PDE4D Q08499 1/20 0.35
F2 P00734 1/20 0.34
F10 P00742 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521424 0.79 ALDH1A1 (0.48) ALDH1A1NPC1LMNARAB9AMAPK1
SCHEMBL4420775 0.78 KDM4E (0.46) ALDH1A1NPC1LMNARAB9AMAPK14
SCHEMBL8003314 0.72 LMNA (0.47) ALDH1A1NPC1LMNAPOLBRAB9A
SCHEMBL17473457 0.71 CNR2 (0.39) CNR2TSHRMAPK14GAACYP4F2
SCHEMBL2449044 0.70 KDM4E (0.61) CNR2NPC1LMNARAB9AMAPK14
SCHEMBL1047777 0.70 CNR2 (0.38) ALDH1A1CNR2TSHRLMNACYP4F2
SCHEMBL7254575 0.70 CNR2 (0.40) ALDH1A1CNR2TSHRLMNAKDM4E
SCHEMBL432964 0.69 KDM4E (0.50) CNR2LMNAPOLBMAPK14KDM4E
SCHEMBL1257733 0.69 KDM4E (0.36) MAPK14KDM4EGRNSORT1ADORA2A
SCHEMBL24915090 0.69 KDM4E (0.47) ALDH1A1NPC1LMNAPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 ALDH1A1 1389/4885CNR2 3438/4885TSHR 283/4885
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 ALDH1A1 1389/4885CNR2 3438/4885TSHR 283/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ALDH1A1 1389/4885CNR2 3438/4885TSHR 283/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ALDH1A1 1389/4885CNR2 3438/4885TSHR 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.